華東醫藥(000963.SZ):公司工業微生物聚焦於合成生物學技術系統應用和生物醫藥創新發展兩大業務場景
格隆匯5月11日丨華東醫藥(000963.SZ)在互動平台表示,公司在工業微生物領域已深耕40餘年,有着深厚的產業基礎和產業轉化能力。公司於2020年設立子公司琿達生物,作為公司工業微生物技術創新平台,並於2023年4月收購南農動藥,快速切入動保領域。公司工業微生物聚焦於合成生物學技術系統應用和生物醫藥創新發展兩大業務場景,已在xRNA、特色原料藥&中間體、大健康&生物材料、動物保健四大領域形成差異化的產品管線和業務解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.